Business
Insilico Medicine's Aliper, Zhavoronkov and Ren to Address AI Forums in Abu Dhabi, Hong Kong and Shanghai
By News Desk ·
Key takeaways
- Insilico Medicine's Alex Aliper, Alex Zhavoronkov and Feng Ren will each speak at a separate international forum in late November 2026.
- Zhavoronkov's Hong Kong keynote is scheduled for November 26, 2026, at CITIC Tower in Admiralty.
- Feng Ren will present on AI-driven drug discovery at the Chinese Society for Cell and Gene Therapy annual meeting in Shanghai on November 26, 2026.
Insilico Medicine's president, chief executive and co-chief executive will each address a separate international conference in late November 2026, covering AI commercialization, capital markets and clinical validation of AI-designed drugs. Scienmag reported the speaking schedule on November 20, 2026.
Aliper's Abu Dhabi Panel on AI Commercialization
Co-Founder and President Dr. Alex Aliper has been invited to the 2026 Momentum and Growth Conference organized by Arabian Business on November 25, 2026, at the Rosewood Abu Dhabi. From 11:30 AM he will join a panel titled "How the UAE is shaping the future of business with AI," which examines how AI moves from national policy into commercial and enterprise outputs, including computing infrastructure, sovereign AI funds and sector-specific pilots.
The Abu Dhabi forum asks whether advanced AI models can be converted into deliverable industrial products. Insilico Medicine's approach combines its Pharma.AI software platform with an automated biology laboratory, linking computational modeling, molecular design, physical experimentation and data feedback into a continuous research cycle that nominates candidate compounds for clinical trials. The gathering is the second edition of The Briefing with Arabian Business, after an inaugural conference in Dubai in June 2026 that drew more than 500 attendees and over 30 speakers.
Zhavoronkov's Hong Kong Capital Markets Keynote
Founder and CEO Dr. Alex Zhavoronkov has been invited to the 2026 Capital Market Hong Kong Forum on November 26, 2026, where he will deliver a keynote from 13:20 to 14:30. China Fund News hosts the event at CITIC Tower in Admiralty under the theme "Breaking Boundaries and Innovating Forward, AI-Empowered Practice: Global Asset Management in Action and Innovation."
Zhavoronkov's keynote will assess AI's shift from technical breakthroughs to large-scale commercial deployments and the structural changes and allocation opportunities that follow for global investors and asset managers. The forum brings together Hong Kong Special Administrative Region government agencies, domestic and international asset management institutions, and global AI technology firms.
Ren's Shanghai Talk on Clinical Validation
Co-CEO and Chief Scientific Officer Dr. Feng Ren will attend the 6th Annual Meeting of the Chinese Society for Cell and Gene Therapy, held from November 26 to 28, 2026, at the Zhangjiang Science Hall in Shanghai. On November 26 at 15:00 he will speak in Track 1, Omics and AI Frontiers for Cell and Gene Therapy, with a keynote titled "From Technological Breakthrough to Clinical Validation: The Second Half of AI-Driven Drug Discovery."
Ren's address covers how research teams use multi-omics datasets and AI for target identification, molecular design and translational drug development. The Cell and Gene Therapy Branch of the Chinese Society for Cell Biology organizes the meeting, which includes plenary keynotes, technical tracks, project roadshows, poster sessions and a Young Elite Forum.
Insilico Medicine's Platform and Listing
Insilico Medicine is a global biotechnology company that combines AI and automated laboratory technologies to speed therapeutic discovery, according to akta.pro company records. The company was founded in 2014 and is headquartered in Boston, with a headcount range of 251-500 and total funding of $624.3 million, the same records show.
Insilico Medicine listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under stock code 03696.HK. It applies its drug discovery work to fibrosis, oncology, immunology, pain, and obesity and metabolic disorders, and extends Pharma.AI into advanced materials, agriculture, nutrition and veterinary medicine.
Earlier Appearances and Pipeline Updates
On November 10, 2026, Scienmag reported that Insilico Medicine announced keynote appearances at global AI drug discovery events in Shanghai, Nanchang and Dubai in November 2026. On October 26, 2026, PR Newswire APAC reported first-in-human Phase 1 data for the pan-TEAD inhibitor ISM6331 at ESMO 2026, with a 40% objective response rate and 68.2% disease control at 130 mg once daily in heavily pretreated mesothelioma.
On October 13, 2026, PR Newswire reported that Insilico Medicine nominated ISM9546, an oral VAV1 molecular glue degrader, as its 35th preclinical candidate since 2021. The compound showed sub-nanomolar degradation potency and reduced disease activity by about 60% in IBD models, with low brain exposure.
Next Steps for Insilico Medicine
The Abu Dhabi conference takes place on November 25, 2026, the Hong Kong forum on November 26, 2026, and the Shanghai meeting runs from November 26 to 28, 2026.